• XXLP Modulates NOX2/ROS/Mitochondria/NLRP3 Axis in Colitis M

  2026-06-13

  Xu Chunfu’s Modified Xianglian Pill (XXLP) demonstrates a targeted anti-inflammatory effect in ulcerative colitis by suppressing the NOX2/ROS/mitochondria/NLRP3 axis and remodeling gut microbiota. This study establishes mechanistic insights into XXLP’s action and suggests new strategies for integrative colitis therapy.

• Fractional Viability Metrics Advance In Vitro Cancer Drug As

  2026-06-12

  Schwartz's dissertation introduces a refined approach to evaluating anti-cancer drug responses by distinguishing between growth inhibition and cell death using fractional viability metrics. This innovation improves the accuracy of in vitro drug testing, with practical implications for research on agents like Bleomycin Sulfate and for studies in pulmonary fibrosis and cancer biology.

• BML-277: Precision Chk2 Inhibitor for DNA Damage Response Re

  2026-06-12

  BML-277 enables robust, ATP-competitive Chk2 inhibition with nanomolar potency, empowering advanced studies on radioprotection of T-cells and cGAS-mediated genome defense. Its stability, selectivity, and actionable protocol parameters make it a premier choice for dissecting DNA damage pathways in cancer and genome integrity research.

• Lumiracoxib (SKU B1458): Reliable COX-2 Inhibition for Cell

  2026-06-11

  This article explores practical laboratory challenges in COX-2 pathway research and demonstrates how Lumiracoxib (SKU B1458) delivers reproducible, data-driven solutions for cell viability and inflammation assays. Drawing on recent peer-reviewed evidence and APExBIO's product specifications, we detail protocol optimization, data interpretation, and vendor selection strategies for robust experimental outcomes.

• Methyl-β-cyclodextrin: Technical Use in Membrane Cholesterol

  2026-06-11

  Methyl-β-cyclodextrin is a high-purity biochemical reagent designed for efficient extraction of cholesterol and certain lipids from cell membranes, supporting studies of membrane fluidity and lipid raft organization. It is not suitable for diagnostic or therapeutic applications; precision in handling and workflow setup is essential for reproducible research outcomes.

• ECL Chemiluminescent Substrate Detection Kit: Precision in W

  2026-06-10

  Unlock ultra-sensitive and reproducible HRP-based protein and nucleic acid detection with the ECL Chemiluminescent Substrate Detection Kit. Discover protocol enhancements and troubleshooting strategies that drive successful chemiluminescent immunoassays, including translational applications in oncology research.

• Clasto-Lactacystin β-lactone: Precision Proteasome Inhibitor

  2026-06-10

  Clasto-Lactacystin β-lactone stands out in proteasome inhibition, offering exceptional potency and irreversibility for dissecting the ubiquitin-proteasome pathway in cellular models. Its unique activity profile empowers robust experimental designs in cancer, neurodegeneration, and immunology, outperforming traditional reversible inhibitors.

• AMPKα2 Links Amino Acid Sensing to Protein Synthesis Inhibit

  2026-06-09

  This study uncovers the isoform-specific role of AMPKα2 in sensing amino acid insufficiency and inhibiting protein synthesis, with implications for neurodegeneration. The findings clarify the mechanistic connection between metabolic stress and Alzheimer’s-like pathology, offering new perspectives for protein phosphorylation analysis in disease models.

• FXR-KLF11 Axis: CDCA Suppresses JAK2/STAT3 in CI-AKI Models

  2026-06-09

  This study reveals that Chenodeoxycholic Acid (CDCA) confers protection against contrast-induced acute kidney injury (CI-AKI) by activating FXR, which upregulates KLF11 to suppress JAK2/STAT3 signaling. The mechanistic insights highlight the FXR-KLF11 axis as a promising target for nephroprotection and inform future translational approaches in metabolic and renal research.

• 4-Ethylphenyl Sulfate: Decoding Biomarker and Assay Complexi

  2026-06-08

  Explore 4-ethylphenyl sulfate as a pivotal tool in gut microbiota-brain interaction research and renal dysfunction biomarker discovery. This article uniquely dissects assay design challenges and practical strategies, grounded in recent advances and nuanced comparative analysis.

• Actinomycin D (A4448): Gold-Standard Transcriptional Inhibit

  2026-06-08

  Actinomycin D is a potent transcriptional inhibitor widely used in cancer research and mRNA stability assays. Its mechanism relies on DNA intercalation and inhibition of RNA polymerase, with robust evidence supporting its role in apoptosis induction and the DNA damage response. APExBIO’s validated Actinomycin D (A4448) provides benchmark reliability for molecular biology workflows.

• 2,2,2-Trichloroethanol: Small Molecule Biochemical in Protei

  2026-06-07

  2,2,2-Trichloroethanol empowers rapid, sensitive protein analysis and translational workflows in neurobiology. Its unmatched solubility and compatibility with advanced imaging and protein detection make it indispensable for reproducible molecular biology research. See how APExBIO’s high-purity reagent redefines troubleshooting, assay setup, and robust experimental design.

• Revolutionizing Pancreatic Cancer Models: Gemcitabine HCl &

  2026-06-06

  This thought-leadership article bridges molecular insight and translational strategy, spotlighting how Gemcitabine HCl (4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one hydrochloride) and multianimal MRI are transforming preclinical pancreatic cancer research. By synthesizing mechanistic rationale, protocol innovation, and workflow optimization, it offers actionable guidance for translational researchers seeking robust, scalable, and reproducible models.

• Nicotinamide Riboside Chloride: Advancing Retinal Disease Mo

  2026-06-05

  This thought-leadership article explores the transformative potential of Nicotinamide Riboside Chloride (NIAGEN) in elevating translational research workflows for retinal and neurodegenerative disease modeling. By integrating mechanistic insight into NAD+ metabolism with strategic guidance for stem cell-derived retinal ganglion cell (RGC) differentiation, we outline a roadmap for researchers to enhance experimental reproducibility, address metabolic dysfunction, and accelerate preclinical discovery. Evidence-backed protocol parameters, competitive landscape analysis, and a visionary outlook contextualize NIAGEN as a next-generation tool for bridging metabolic and neurodegenerative research domains.

• Clathrin-Mediated Entry of Grass Carp Reovirus: Inhibitor In

  2026-06-05

  Wang et al. (2018) rigorously demonstrate that genotype III grass carp reovirus (GCRV104) enters host cells via clathrin-mediated endocytosis, independent of actin cytoskeleton disruption. This work clarifies the entry mechanism of an important aquatic pathogen and refines experimental strategies for dissecting viral-cell interactions in cytoskeletal research.

455 records 15/31 page Previous Next First page 上5页 1112131415 下5页 Last page